Abstract
AIMS: This study aims to investigate the underlying mechanisms of abnormal expression of α-synuclein (α-syn) in cortical lesions of focal cortical dysplasia IIb (FCD IIb) and tuberous sclerosis complex (TSC). METHODS: Cortical lesions of patients with FCD IIb and TSC were obtained during the surgery, FCD rats were generated by in utero X-ray radiation. Immunostaining, RT-PCR, Western blotting, and electroencephalography recording were conducted in this study. α-syn was intraventricularly injected; mTOR inhibitor (rapamycin) and glutamate transporter-1 (GLT-1) enhancer (ceftriaxone sodium) were intraperitoneally injected before the following experiments. RESULTS: mTOR and p-mTOR expressed in the dysmorphic neurons, vimentin-positive balloon cells, and giant cells, whereas the mTOR/p-mTOR ratio was decreased in FCD IIb and TSC lesions. α-syn was decreased, while p-α-syn was increased in the cortex of FCD animals, whereas they were rescued by inhibition of mTOR with rapamycin. The expression of GLT-1 was decreased and modulated by rapamycin in FCD animals. Enhancement of the function of GLT-1 with ceftriaxone ameliorated α-synucleinopathy and seizure activities in FCD animals. Additionally, intracerebroventricular injection of α-syn exerted anti-seizure effects. CONCLUSIONS: Our results showed that modulation of the mTOR/GLT-1 pathway ameliorated α-synucleinopathy and seizure activities in FCD, providing insights for understanding the epileptogenic mechanisms of FCD IIb and TSC.